Platform Architecture

Five layers, one axis
unified compliance science infrastructure for drugs and devices

Seno.Bio isn't a provider of any single service — it's platform-grade infrastructure built on compliance science, spanning the full journey of biopharma and medtech projects from validation to industrialization.

Core Positioning

In One Sentence

GLP is our compliance hub, compliance science is our core logic —
connecting translation → validation → certification → industrialization → capitalization
as one full-chain platform operator

WE ARE NOT
  • A standalone GLP testing lab
  • An independent organoid company
  • A traditional CDMO contract manufacturer
  • A fragmented CRO service provider
WE ARE
  • A compliance science platform operator
  • Unified validation infrastructure for drugs and devices
  • A full-chain project funnel platform
  • An ecosystem driven by services and capital together
Platform Structure

The Five Layers, in Detail

①
Project Translation — Translation & Validation Platform
Platform entry layer · A steady source of projects

The problem we solve: where do good projects keep coming from? We're not an incubator or an accelerator — we're an industrial translation platform that steps in early, building relationships before a project is even fully formed.

Institutional Partnerships
Translation agreements with universities and research institutes
Industrial Park Sourcing
Bringing in promising incubated projects through park partners
In-House Incubation
Incubating early-stage directions ourselves
②
Validation Enhancement — The Organoid Layer
A leap in validation efficiency · An upstream GLP enhancement tool

Redefining the category: not a standalone business, not futuristic tech — a leap forward in validation efficiency. Organoids are an upstream tool that strengthens GLP, not a parallel track competing with it.

Lower failure rates
Efficient in vitro screening sharply cuts the failure rate of projects entering GLP, saving on validation costs
First-mover on new standards
Positioning early around the emerging OECD organoid validation guidelines to secure a first-mover advantage on the next generation of compliance standards
Learn about organoid services
★
Compliance Validation — The GLP Core Hub
A shared compliance hub for drugs and devices · ICH + ISO 10993, dual-track coverage

Why it's the core hub: GLP is the only node that connects drug compliance (ICH) and device compliance (ISO 10993) — the natural meeting point where both tracks converge, solving the fundamental problem of unifying drugs and devices on one platform.

Drug Track — ICH Framework
Toxicology (ICH S2/S5/S6) · Safety pharmacology (ICH S7) · PK/PD studies
Device Track — ISO 10993
Cytotoxicity · Sensitization · Genotoxicity · Implantation · Full biocompatibility evaluation
Learn more about GLP services
④
Industrialization — The CDMO Layer
Real manufacturing capability · Continuity of value, not contract work

The key shift: what we sell isn't capacity — it's the value of continuity: a project moving seamlessly from finished validation straight into industrialization, on the same platform, with no need to find an outside manufacturer.

Process development & scale-up GMP-grade sample production CMC documentation Biologics manufacturing Cell therapy products Tissue-engineered products
Learn about CDMO services
⑤
Capital Extension — Growth Co-Investment
How the platform captures the value it creates · Operator logic, not VC

The core logic: a project enters the platform, goes through validation and GLP compliance, moves into industrialization — and along the way, if it turns out to be a strong one, we deepen the relationship through Growth Co-Investment, exiting through capitalization once the project succeeds. This isn't chasing deals like a VC — it's recognizing strong projects already inside the platform and choosing to go deeper with them (operator logic).

Steady service revenue
GLP service fees + organoid testing fees + CDMO manufacturing fees
High-upside equity returns
Growth Co-Investment exit returns · Layered on top of steady cash flow
Compliance science as core logic · Data assets that compound into a moat · A flywheel effect: more projects → more data → higher success rates → more projects attracted
Unifying Drugs and Devices

Drugs and Devices — Different Project Types, One Platform

Platform Layer Drug Track Device Track
① TranslationResearch institute translationDevice R&D institution sourcing
② Validation EnhancementOrganoid efficacy screeningOrganoid biocompatibility assessment
★ ③ Compliance ValidationGLP (ICH S series)GLP (ISO 10993 series)
④ IndustrializationCDMO biologics manufacturingTissue engineering / advanced therapy manufacturing
⑤ Capital ExtensionGrowth Co-InvestmentGrowth Co-Investment

Both project types use the same platform infrastructure — they just follow different regulatory standards

See how the platform can serve your project
Whether it's a drug or a device, the platform has a precise service path for every stage
Book a Platform Consultation See GLP Services
↑